Completed OBSERVATIONAL NCT01340443

An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL

Sponsor: Hoffmann-La Roche

Conditions Diffuse Large B-Cell Lymphoma

Updated 7 times since 2017 Last updated: Nov 9, 2017 Started: Jan 19, 2011 Primary completion: Jul 15, 2016 Completion: Jul 15, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Diffuse Large B-Cell Lymphoma, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 7 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 2 earlier versions

Dec 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Dec 2017 [monthly]

Completed NA

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Changzhou, China , Daqing, China , Foshan, China , Fuzhou, China , Guangzhou, China , Guiyang, China , Hangzhou, China and 12 more locations